<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">919</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2023-13-3-98-105</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL CASE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Primary squamous cell carcinoma of the parotid salivary gland: a clinical observation</article-title><trans-title-group xml:lang="ru"><trans-title>Первичный плоскоклеточный рак околоушной слюнной железы: клиническое наблюдение</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4045-1247</contrib-id><name-alternatives><name xml:lang="en"><surname>Ognerubov</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Огнерубов</surname><given-names>Н. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Nikolay A. Ognerubov </bold></p><p><italic>93 Sovetskaya St., Tambov 392000</italic></p></bio><bio xml:lang="ru"><p><bold>Николай Алексеевич Огнерубов </bold></p><p><italic>392000 Тамбов, ул. Советская, 93</italic></p></bio><email>ognerubov_n.a@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-8229-2179</contrib-id><name-alternatives><name xml:lang="en"><surname>Khizhnyak</surname><given-names>A. O.</given-names></name><name xml:lang="ru"><surname>Хижняк</surname><given-names>А. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>93 Sovetskaya St., Tambov 392000</italic></p></bio><bio xml:lang="ru"><p><italic>392000 Тамбов, ул. Советская, 93</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0576-5451</contrib-id><name-alternatives><name xml:lang="en"><surname>Ognerubova</surname><given-names>М. A.</given-names></name><name xml:lang="ru"><surname>Огнерубова</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>29с Moskovskaya St., Tambov 392000</italic></p></bio><bio xml:lang="ru"><p><italic>392000 Тамбов, ул. Московская, 29в</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-2832-0557</contrib-id><name-alternatives><name xml:lang="en"><surname>Sergeev</surname><given-names>R. S.</given-names></name><name xml:lang="ru"><surname>Сергеев</surname><given-names>Р. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>93 Sovetskaya St., Tambov 392000</italic></p></bio><bio xml:lang="ru"><p><italic>392000 Тамбов, ул. Советская, 93</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-3309-6866</contrib-id><name-alternatives><name xml:lang="en"><surname>Polyakova</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Полякова</surname><given-names>Л. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>93 Sovetskaya St., Tambov 392000</italic></p></bio><bio xml:lang="ru"><p><italic>392000 Тамбов, ул. Советская, 93</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Derzhavin Tambov State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Тамбовский государственный университет им. Г.Р. Державина»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Tambov Regional Oncological Clinical Dispensary</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Тамбовский областной онкологический клинический диспансер»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-12-12" publication-format="electronic"><day>12</day><month>12</month><year>2023</year></pub-date><volume>13</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>98</fpage><lpage>105</lpage><history><date date-type="received" iso-8601-date="2023-12-11"><day>11</day><month>12</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-12-11"><day>11</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Ognerubov N.A., Khizhnyak A.O., Ognerubova М.A., Sergeev R.S., Polyakova L.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Огнерубов Н.А., Хижняк А.О., Огнерубова М.А., Сергеев Р.С., Полякова Л.В.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Ognerubov N.A., Khizhnyak A.O., Ognerubova М.A., Sergeev R.S., Polyakova L.V.</copyright-holder><copyright-holder xml:lang="ru">Огнерубов Н.А., Хижняк А.О., Огнерубова М.А., Сергеев Р.С., Полякова Л.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/919">https://ogsh.abvpress.ru/jour/article/view/919</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>Malignant tumors of the salivary glands account for 3–5 % of all cases of head and neck cancer. Squamous cell carcinoma is the rarest histological variant of this pathology. It accounts for an average of 1.6 %. Among large salivary gland tumors, squamous cell carcinoma most often occurs in the parotid salivary gland.</p><p><bold>Aim. </bold>To present a clinical case of primary disseminated cancer of the parotid salivary gland with squamous cell structure.</p><p><bold>Clinical observation. </bold>A 70-year-old patient was under observation who was diagnosed with a primary squamous cell tumor of the parotid salivary gland with multiple metastases during a complex examination. He was sick for about 6 months when asymmetry of left half of the face appeared due to a painful neoplasm in the parotid salivary gland. Recently, the patient has noted increased tumor growth. Objective examination revealed peripheral paralysis of the facial nerve on the left. In the parotid-masticatory region on the left, with a transition to the zygomatic region, there is a dense painful immobile exophytic tumor with infiltration into soft tissues of the face and skin 6.5 × 5.0 cm in size with an ulcer in the center. Laterally, it reaches the tragus, and at the bottom-the angle of the lower jaw. In the submandibular region on the left, metastatic lymph nodes 2.5 × 2.0 cm in size are palpated. A biopsy was collected. Histological conclusion: non-keratinizing squamous cell carcinoma. Expression of the programmed death receptor ligand (PD-L1) in the tumor is negative. Mutations of genes Her2-neu and BRAF were not detected. According to medical imaging methods, multiple metastases were found in the lungs, liver, zygomatic bone and tumor growth in the maxillary sinus on the left. The diagnosis was established: cancer of the parotid salivary gland, stage IVC, cT4N1M1, with metastases to the liver, lungs and bones. Polychemotherapy was prescribed according to the scheme: 5-fluorouracil + cisplatin + cetuximab + bisphosphonates. After 3 cycles, a partial regression is obtained.</p><p><bold>Conclusion. </bold>The primary squamous cell carcinoma is prone to an aggressive course and has an unfavorable prognosis, especially in patients over 60 years of age with skin and facial nerve damage, as well as the presence of regional and distant metastases. Differential diagnosis is necessary to exclude the secondary nature of the tumor. The presented case is a rare example of primary squamous cell carcinoma of the parotid salivary gland with extensive metastatic lesion and regression of the pathological process after polychemotherapy in combination with targeted therapy.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>злокачественные опухоли слюнных желез составляют 3–5 % всех случаев рака головы и шеи. плоскоклеточный рак является наиболее редким гистологическим вариантом данной патологии. На его долю в среднем приходится 1,6 %. среди опухолей больших слюнных желез плоскоклеточный рак чаще всего возникает в околоушной слюнной железе.</p><p><bold>Цель </bold>– представить клинический случай первичного диссеминированного рака околоушной слюнной железы плоскоклеточного строения.</p><p><bold>Клиническое наблюдение. </bold>под наблюдением находился больной, 70 лет, у которого при комплексном обследовании установлена первичная плоскоклеточная опухоль околоушной слюнной железы со множественными метастазами. болен около 6 мес, когда появилась асимметрия левой половины лица из-за болезненного новообразования в области околоушной слюнной железы. В последнее время пациент отмечал усиленный рост опухоли. при объективном осмотре выявлен периферический паралич лицевого нерва слева. В околоушно-жевательной области слева с переходом на скуловую область имеется плотная болезненная неподвижная экзофитная опухоль с инфильтрацией мягких тканей лица и кожи размерами 6,5 × 5,0 см, с изъязвлением в центре. латерально она достигает козелка, а внизу – угла нижней челюсти. В подчелюстной области слева пальпируются лимфатические узлы метастатического характера размерами 2,5 × 2,0 см. Выполнена биопсия. гистологическое заключение: плоскоклеточный неороговевающий рак. Экспрессия лиганда рецептора программируемой клеточной гибели 1 (programmed death-ligand 1, PD-L1) в опухоли отрицательная. мутации генов <italic>Her2-neu </italic>и <italic>BRAF </italic>не выявлены. по данным методов медицинской визуализации обнаружены множественные метастазы в легких, печени, скуловой кости, прорастание опухоли в верхнечелюстную пазуху слева. установлен диагноз: рак околоушной слюнной железы, стадия IVс, сT4N1M1, с метастазами в печень, легкие и кости. Назначена полихимиотерапия по схеме: 5-фторурацил + цисплатин + цетуксимаб + бисфосфонаты. после 3 циклов получена частичная регрессия.</p><p><bold>Заключение. </bold>первичный плоскоклеточный рак склонен к агрессивному течению и имеет неблагоприятный прогноз, особенно у пациентов старше 60 лет с поражением кожи, лицевого нерва, а также наличием регионарных и отдаленных метастазов. Дифференциальная диагностика необходима для исключения вторичного характера опухоли. представленный случай является редким примером первичного плоскоклеточного рака околоушной слюнной железы с обширным метастатическим поражением и регресса патологического процесса после полихимиотерапии в сочетании с таргетной терапией.</p></trans-abstract><kwd-group xml:lang="en"><kwd>parotid salivary gland</kwd><kwd>primary cancer</kwd><kwd>metastatic cancer</kwd><kwd>squamous cell carcinoma</kwd><kwd>facial nerve paralysis</kwd><kwd>chemotherapy</kwd><kwd>targeted therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>околоушная слюнная железа</kwd><kwd>первичный рак</kwd><kwd>метастатический рак</kwd><kwd>плоскоклеточный рак</kwd><kwd>паралич лицевого нерва</kwd><kwd>химиотерапия</kwd><kwd>таргетная терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Boukheris H., Curtis R.E., Land C.E. et al. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 2009;18(11):2899–906. DOI: 10.1158/1055-9965.EPI-09-0638</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Żurek M., Fus Ł., Niemczyk K. et al. Salivary gland pathologies: evolution in classification and association with unique genetic alterations. Eur Arch Otorhinolaryngol 2003;280(11):4739–50. DOI: 10.1007/s00405-023-08110-w</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lin H.H., Limesand K.H., Ann D.K. Current State of knowledge on salivary gland cancers. Crit Rev Oncol 2018;23(3–4):139–51. DOI: 10.1615/CritRevOncog.2018027598</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Batsakis J.G. Primary squamous cell carcinomas of major salivary glands. Ann Otol Rhinol Laryngol 1983;92(1, Pt. 1):94–5. DOI: 10.1177/000348948309200123</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Orell S.R., Klijanienko J. Head and neck; salivary glands. In: Orell &amp; Sterrett’s fine needle aspiration cytology. Ed. by S.R. Orell, G.F. Sterrett. 5th edn. New Delhi: Churchill Livingstone Elsevier, 2012. Pp. 70–71.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mallon D.H., Kostalas M., MacPherson F.J. et al. The diagnostic value of fine-needle aspiration in parotid lumps. Ann R Coll Surg Engl 2013;95(4):258–62. DOI: 10.1308/003588413X13511609958370</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Tahiri I. et al. Squamous cell carcinoma of the submandibular gland with cutaneous fistula: a case report and literature review. Cureus 2022;14(8):e27785. DOI: 10.7759/cureus.27785</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Rabinov J.D. Imaging of salivary gland pathology. Radiol Clin North Am 2000;38(5):1047–57. DOI: 10.1016/S0033-8389(05)70220-7</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Celebi I., Mahmutoglu A.S., Ucgul A. et al. Quantitative diffusionweighted magnetic resonance imaging in the evaluation of parotid gland masses: a study with histopathological correlation. Clin Imaging 2013;37(2):232–8. DOI: 10.1016/j.clinimag.2012.04.025</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Toriihara A., Nakamura S., Kubota K. et al. Can dual-time-point 18F-FDG PET/CT differentiate malignant salivary gland tumors from benign tumors? AJR Am J Roentgenol 2013;201(3):639–44. DOI: 10.2214/AJR.12.10395</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Jeong H.S., Chung M.K., Son Y.I. et al. Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies. J Nucl Med 2007;48(8):1237–44. DOI: 10.2967/jnumed.107.041350</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Taxy J.B. Squamous carcinoma in a major salivary gland: a review of the diagnostic considerations. Arch Pathol Lab Med 2001;125(6):740–5. DOI: 10.5858/2001-125-0740-SCIAMS</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Spiro R.H. Management of malignant tumors of the salivary glands. Oncology (Huntingt) 1998;12(5):671–83.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Sirjani D.B., Lewis J.S., Beadle B.M., Sunwoo J.B. Malignant neoplasms of the salivary glands. In: Cummings Otolaryngology Head &amp; Neck Surgery. Ed. by P.W. Flint, W. Charles 7th edn. 2021. Vol. 2. Part VI. Рp. 1209–1212.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Colella G., Cannavale R., Flamminio F., Foschini M.P. Fine-needle aspiration cytology of salivary gland lesions: a systematic review. J Oral Maxillofac Surg 2010;68(9):2146–53. DOI: 10.1016/j.joms.2009.09.064</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kurabayashi T., Ida M., Tetsumura A. et al. MR imaging of benign and malignant lesions in the buccal space. Dentomaxillofac Radiol 2002;31(6):344–9. DOI: 10.1038/sj.dmfr.4600723</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Mezi S., Pomati G., Botticelli A. et al. Primary squamous cell carcinoma of major salivary gland: “Sapienza Head and Neck Unit” clinical recommendations. Rare Tumors 2020;12:2036361320973526. DOI: 10.1177/2036361320973526</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Bell D., Hanna E.Y., Miele L. et al. Expression and significance of notch signaling pathway in salivary adenoid cystic carcinoma. Ann Diagn Pathol 2014;18(1):10–3. DOI: 10.1016/j.anndiagpath.2013.10.001</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Shemen L.J., Huvos A.G., Spiro R.H. Squamous cell carcinoma of salivary gland origin. Head Neck Surg 1987;9(4):235–40. DOI: 10.1002/hed.2890090407</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Gilbert J., Li Y., Pinto H.A. et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 2006;28(3):197–204. DOI: 10.1002/hed.20327</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Son E., Panwar A., Mosher C.H., Lydiatt D. Cancers of the major salivary gland. J Oncol Pract 2018;14(2):99–108. DOI: 10.1200/JOP.2017.026856</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Locati L.D., Bossi P., Perrone F. et al. Cetuximab in recurrent and/ or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2009;45(7):574–8. DOI: 10.1016/j.oraloncology.2008.07.010</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Dalin M.G., Watson P.A., Ho A.L., Morris L.G. Androgen receptor signaling in salivary gland cancer. Cancers (Basel) 2017;9(2):17. DOI: 10.3390/cancers9020017</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Kondo Y., Kikuchi T., Esteban J.C., Kumaki N. et al. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma. Pathol Int 2014;64(9):453–9. DOI: 10.1111/pin.12195</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Thorpe L.M., Schrock A.B., Erlich R.L. et al. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2- amplified salivary gland cancer and a review of the literature. Head Neck 2017;39(3):E40–4. DOI: 10.1002/hed.24634</mixed-citation></ref></ref-list></back></article>
